信达生物（01801）：公司信息更新报告：2025年公司实现全面盈利，全球化战略加速推进

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved total revenue of 13.042 billion HKD in 2025, marking a year-on-year growth of 38.4%. Product sales revenue reached 11.896 billion HKD, up 44.6% year-on-year. The company reported a net profit of 814 million HKD under IFRS, compared to a loss of 95 million HKD in 2024. Non-IFRS net profit was 1.723 billion HKD. The growth is attributed to the company's leading position in oncology products and the rapid expansion of its cardiovascular and metabolic product lines [6][10] - The company has accelerated its globalization strategy, with key products entering global multi-regional clinical trials (MRCT). The core product IBI363 has initiated a global MRCT Phase III clinical study, while IBI343 has received breakthrough therapy designation (BTD) from NMPA and fast track designation (FTD) from the FDA [7][8] - The company has a strong pipeline focusing on innovative therapies in oncology, with multiple products expected to enter international Phase I clinical trials. The next-generation pipeline includes IBI363, IBI343, and others, aimed at addressing unmet medical needs [8] Financial Summary - In 2025, the company achieved a total revenue of 13.042 billion HKD, with a year-on-year growth of 38.4%. The projected revenues for 2026 and 2027 are 18.515 billion HKD and 21.515 billion HKD, respectively [10] - The net profit for 2026 is projected to be 2.178 billion HKD, with further growth expected in subsequent years, reaching 2.504 billion HKD in 2027 and 2.960 billion HKD in 2028 [10] - The company's gross margin is expected to remain high, with projections of 86.8% in 2026 and 86.6% in 2027 [10]